Company intelligence / Profile preview

杭州多域生物技术

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Multiway Bio is a clinical-stage biotechnology company headquartered in Hangzhou, China, focused on the discovery and development of innovative protein degradation therapies. The company utilizes its proprietary Targeted Protein Degradation (TPD) platform to develop bifunctional molecules, including PROTACs and molecular glues, aimed at addressing undruggable targets in oncology and immunology. Their lead program is a next-generation BTK degrader currently in clinical trials for B-cell malignancies. Multiway Bio is supported by prominent venture capital firms and maintains a robust pipeline of small molecule degraders for various cancers and inflammatory conditions.

Therapeutic areas: ImmunologyOncology
Modalities: Small moleculeProteolysis-targeting chimera therapyMolecular glue therapy
Industry: Biotech

Beyond the preview

Go deeper on 杭州多域生物技术.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 杭州多域生物技术.

Explore the full profile